<code id='31C3D40079'></code><style id='31C3D40079'></style>
    • <acronym id='31C3D40079'></acronym>
      <center id='31C3D40079'><center id='31C3D40079'><tfoot id='31C3D40079'></tfoot></center><abbr id='31C3D40079'><dir id='31C3D40079'><tfoot id='31C3D40079'></tfoot><noframes id='31C3D40079'>

    • <optgroup id='31C3D40079'><strike id='31C3D40079'><sup id='31C3D40079'></sup></strike><code id='31C3D40079'></code></optgroup>
        1. <b id='31C3D40079'><label id='31C3D40079'><select id='31C3D40079'><dt id='31C3D40079'><span id='31C3D40079'></span></dt></select></label></b><u id='31C3D40079'></u>
          <i id='31C3D40079'><strike id='31C3D40079'><tt id='31C3D40079'><pre id='31C3D40079'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:12
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          Lilly's Alzheimer's drug donanemab backed by FDA advisers
          Lilly's Alzheimer's drug donanemab backed by FDA advisers

          DarronCummings/APAdviserstotheFoodandDrugAdministrationvoted11-0onMondaytorecommendtheapprovalofadru

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Readers discuss the intersection of pregnancy and addiction

          MollyFergusonforSTATFirstOpinionisSTAT’splatformforinteresting,illuminating,andmaybeevenprovocativea